Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-91633 in R/R AML and R/R HR-MDS
NCT04951778Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Dec 2021
- Primary completion
- Jul 2025
- Modality
- Molecular Glues
- Countries
- 2
01
Overview
Phase 1, open-label trial of CC-91633 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Tolerated Dose up to 2 years, Dose-limiting Toxicity up to 42 days and 1 more. Started Dec 2021; status: terminated.
02
Drugs
CC-91633
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04951778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951778.